packageIbritumomabTiuxetan

ibritumomab tiuxetan

Extends from Pharmacolibrary.Interfaces.PartialSubstance (Identity and physicochemical constants of one drug (Drugs.Substances)).

Information

Ibritumomab tiuxetan is a radioimmunotherapy drug, a monoclonal antibody radiopharmaceutical used to treat follicular lymphoma. It is an approved medication, though its European Union marketing authorisation has lapsed, so its use is now limited mainly to the United States.

Summary written by glm-5.3-flash from Wikidata Q635415 and the WHO ATC classification and the EMA medicines list; not checked by a person.

name:ibritumomab tiuxetan
ATC codes:V10XX02
DrugBank:DB00078
Wikidata:Q635415

Parameters

TypeNameDefaultDescription
Stringname (from PartialSubstance)""INN / common name
String[:]atcCodes (from PartialSubstance)fill("", 0)all WHO ATC codes of the drug
StringdrugbankId (from PartialSubstance)""e.g. DB00758
StringpubchemCid (from PartialSubstance)""PubChem compound id
StringchebiId (from PartialSubstance)""ChEBI id (number)
StringwikidataId (from PartialSubstance)""e.g. Q410238
Stringformula (from PartialSubstance)""molecular formula
Modelica.Units.SI.MolarMassM (from PartialSubstance)0molar mass; 0 = unknown
ReallogP (from PartialSubstance)Modelica.Constants.infoctanol-water partition coefficient (log10); inf = unknown